Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsitePK68 is a potent orally active and specific inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90 nM.
More Information Supplier PagePKC-theta inhibitor (compound 20) inhibits PKC-θ with an IC50 of 18 nM.
More Information Supplier PagePKC-theta inhibitor (compound 20) inhibits PKC-θ with an IC50 of 18 nM.
More Information Supplier PagePKC-theta inhibitor (compound 20) inhibits PKC-θ with an IC50 of 18 nM.
More Information Supplier PagePKC-theta inhibitor (compound 20) inhibits PKC-θ with an IC50 of 18 nM.
More Information Supplier PagePKC-theta inhibitor (compound 20) inhibits PKC-θ with an IC50 of 18 nM.
More Information Supplier PagePKC-theta inhibitor (compound 20) inhibits PKC-θ with an IC50 of 18 nM.
More Information Supplier PagePKG drug G1 is an activater of Protein Kinase G Iα (PKG Iα) targeting C42, resulting vasodilation and blood pressure lowering.
More Information Supplier PagePKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM.
More Information Supplier PagePKI 14-22 amide, myristoylated is a potent cAMP-dependent PKA inhibitor, which can reduce the IgG-mediated phagocytic response and also inhibits neutrophil adhesion.
More Information Supplier PagePKI 14-22 amide, myristoylated is a potent cAMP-dependent PKA inhibitor, which can reduce the IgG-mediated phagocytic response and also inhibits neutrophil adhesion.
More Information Supplier PagePKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively; also potent to PI3Kα mutants E545K and H1047R.
More Information Supplier PagePKM2 inhibitor(Compound 3K, PKM2-IN-1) displays PKM2 inhibitory activity with the IC50 value of 2.95 μM. The IC50 value for PKM1 is 4-5-fold higher than that for PKM2.
More Information Supplier PagePKM2 inhibitor(Compound 3K, PKM2-IN-1) displays PKM2 inhibitory activity with the IC50 value of 2.95 μM. The IC50 value for PKM1 is 4-5-fold higher than that for PKM2.
More Information Supplier PagePKM2 inhibitor(Compound 3K, PKM2-IN-1) displays PKM2 inhibitory activity with the IC50 value of 2.95 μM. The IC50 value for PKM1 is 4-5-fold higher than that for PKM2.
More Information Supplier PagePKM2 inhibitor(Compound 3K, PKM2-IN-1) displays PKM2 inhibitory activity with the IC50 value of 2.95 μM. The IC50 value for PKM1 is 4-5-fold higher than that for PKM2.
More Information Supplier PagePKR-IN-2 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160, which can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia.
More Information Supplier PagePKR-IN-C16 (imoxin, C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.
More Information Supplier PagePKR-IN-C16 (imoxin, C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.
More Information Supplier PagePKR-IN-C16 (imoxin, C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.
More Information Supplier PagePKR-IN-C16 (imoxin, C16, Imidazolo-oxindole PKR inhibitor C16) is a specific inhibitor of RNA-dependent protein kinase (PKR, Protein Kinase R, EIF2AK2). PKR-IN-C16 prevents apoptosis and IL-1β production in an acute excitotoxic rat model with a neuroinflammatory component.
More Information Supplier PageA unique collection of 796 plant extracts for high throughput screening (HTS) and high content screening (HCS).
More Information Supplier PagePlantaginis Herba Extract is obtained from the dried whole plant of Plantaginaceae family, is famous for the curative effects in promoting urination and treating stranguria in traditional Chinese medicine.
More Information Supplier PagePlantaginis Semen Extract is drawed from Plantaginis Semen, has significant effects on anti-hyperuricemia, anti-inflammatory and renal protection, and attenuates potassium oxonate-induced hyperuricemia through regulation of lipid metabolism disorder.
More Information Supplier PagePlantagoside, a flavanone glucoside isolated from the seeds of Plantago asiatica, is a specific and non-competitive alpha-mannosidase inhibitor with IC50 of 5 μM.
More Information Supplier PagePlantamajoside (Y0160, C10485), a hydroxycinnamic acid, is used as a biomarker in chemotaxonomical studies, and is a compound with numerous biological applications and considerable pharmacological potential.
More Information Supplier PagePlatycladi Cacumen Extract is extracted from Platycladi Cacumen, which has been traditionally used to resist alopecia and promote hair growth.
More Information Supplier PagePlatycodin D, the main saponin isolated from Chinese herb Platycodonis Radix, exhibits anti-inflammatory, anti-allergic, cholesterol-lowering and neuroprotective properties.
More Information Supplier PagePlecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis.
More Information Supplier PagePleconaril (APO-P001, Picovir, VP 63843, WIN 63843) is a capsid inhibitor used previously to treat enterovirus infections. Pleconaril is effective in inhibiting replication with IC50 of < 0.050 μM.
More Information Supplier PagePlerixafor (AMD3100, JM 3100, SID791) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor inhibits human immunodeficiency virus (HIV) replication.
More Information Supplier PagePlerixafor (AMD3100, JM 3100, SID791) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor inhibits human immunodeficiency virus (HIV) replication.
More Information Supplier PagePlerixafor (AMD3100, JM 3100, SID791) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor inhibits human immunodeficiency virus (HIV) replication.
More Information Supplier PagePlerixafor (AMD3100, JM 3100, SID791) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor inhibits human immunodeficiency virus (HIV) replication.
More Information Supplier PagePlerixafor (AMD3100, JM 3100,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.
More Information Supplier PagePlerixafor (AMD3100, JM 3100,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.
More Information Supplier PagePlerixafor (AMD3100, JM 3100,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.
More Information Supplier PagePleuromutilin (Drosophilin B, Mutilin 14-glycolate), the lead compound for novel antibiotics, inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit of bacteria.
More Information Supplier PagePleurotus eryngii Extract is derived from Pleurotus eryngii, which manages neurological disorders such as dementia, Alzheimer’s and Parkinson’s diseases.
More Information Supplier PagePleurotus ostreatus Extract is extracted from Pleurotus ostreatus, which decreases the proliferation of leukaemia cells through apoptosis.
More Information Supplier PagePlinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
More Information Supplier PagePlinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
More Information Supplier PagePlinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
More Information Supplier PagePlinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
More Information Supplier PagePlinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
More Information Supplier PagePlonmarlimab (Anti-CSF2 / GM-CSF) is a monoclonal antibody targeting GM-CSF. It can be used for research of rheumatoid arthritis and COVID-19. MW :145.96 KD.
More Information Supplier PagePlonmarlimab (Anti-CSF2 / GM-CSF) is a monoclonal antibody targeting GM-CSF. It can be used for research of rheumatoid arthritis and COVID-19. MW :145.96 KD.
More Information Supplier PagePlonmarlimab (Anti-CSF2 / GM-CSF) is a monoclonal antibody targeting GM-CSF. It can be used for research of rheumatoid arthritis and COVID-19. MW :145.96 KD.
More Information Supplier PagePlozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD.
More Information Supplier PagePlozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD.
More Information Supplier Page
